Table 1 Characteristics of patients underwent trimodality treatment
Characteristics | Total n = 50 | Pathological complete response (pCR) n = 18 | Pathological partial response (pPR) n = 32 | P value |
|---|---|---|---|---|
Age (years) | 56.67 ± 7.66 | 58.06 ± 7.79 | 0.544 | |
Gender | ||||
Male | 43 | 16 (88.9%) | 27 (84.4%) | 0.505 |
Female | 7 | 2 (11.1%) | 5 (15.6%) | |
BMI (kg/m2) | 23.47 ± 4.16 | 20.31 ± 3.62 | 0.007 | |
Differentiation | ||||
Well | 2 | 1 (5.6%) | 1 (3.1%) | 0.875 |
Moderate | 24 | 9 (50%) | 15 (46.9%) | |
Poor | 24 | 8 (44.4%) | 16 (50%) | |
Post-nCRT EUS T stage | ||||
T1 | 6 | 4 (33.3%) | 2 (9.5%) | 0.107 |
T2 | 15 | 6 (50%) | 9 (42.9%) | |
T3 | 12 | 2 (16.7%) | 10 (47.6%) | |
Post-nCRT EUS N stage | ||||
N0 | 26 | 10 (47.1%) | 16 (51.9%) | 0.494 |
N + | 7 | 2 (52.9%) | 5 (48.1%) | |
ypTNM stage | ||||
I + II (early) | 36 | 18 (100%) | 18 (56.3%) | 0.001 |
III + IV (advanced) | 14 | 0 (0%) | 14 (43.8%) | |
Radiotherapy dose (Gy) | 48.53 ± 3.99 | 48.12 ± 4.80 | 0.760 | |
Pre-nCRT SUVmax | 11.32 ± 4.66 | 13.57 ± 7.41 | 0.250 | |
Post-nCRT SUVmax | 2.06 ± 1.83 | 4.76 ± 2.41 | < 0.001 | |
< 3 | 17 | 11 (61.1%) | 6 (18.8%) | 0.003 |
≥ 3 | 33 | 7 (38.9%) | 26 (81.3%) | |
ΔSUV ratioa | 0.83 ± 0.16 | 0.48 ± 0.81 | 0.077 | |
Lymphovascular invasion (LVSI) | ||||
Yes | 3 | 0 (0%) | 3 (9.4%) | 0.253 |
No | 47 | 18 (100%) | 29 (90.6%) | |
Extracapsular extension of metastatic lymph nodes | ||||
Yes | 7 | 0 (0%) | 7 (21.9%) | 0.034 |
No | 43 | 18 (100%) | 25 (78.1%) | |
Numbers of dissected lymph nodes | 11.33 ± 5.76 | 13.27 ± 7.52 | 0.354 | |